Science
Mechanism of Action
Identified as SIG1459, this isoprenylcysteine (IPC) small molecule addresses acne through a multifaceted approach. Its mechanism involves direct antibacterial activity against *Cutibacterium acnes* and the inhibition of Toll-Like Receptor 2 (TLR2) inflammatory signaling. By effectively suppressing TLR2, it reduces the production of key pro-inflammatory cytokines, specifically IL-8 and IL-1α, within human keratinocytes, thereby intervening in critical steps of comedogenesis and inflammation associated with acne vulgaris.
Research
Clinical Evidence
Medium confidence1%
Key findings
- 01 A vehicle-controlled clinical study demonstrated significant anti-acne activity upon topical application at a 1% concentration. In vitro investigations further revealed potent antibacterial efficacy against *Cutibacterium acnes*, evidenced by a minimal inhibitory concentration (MIC) of 8.5 μmol/L, a minimal bactericidal concentration (MBC) of 16.1 μmol/L, and a minimal biofilm eradication concentration (MBEC) of 12.5 μmol/L. Additionally, in human keratinocytes, it effectively inhibited TLR2-induced release of pro-inflammatory cytokines, with IC50 values of 0.086 μmol/L for IL-8 (TLR2/TLR2) and 0.209 μmol/L for IL-8 (TLR2/6), and an IC50 of 0.050 μmol/L for IL-1α (TLR2/TLR2).
Transparency
Dusting Analysis
The Formula
Formulation
Safety
Safety Profile
While formal safety assessments by major regulatory bodies such as CIR, SCCS, or FDA are not yet available, INCI Beauty reports no penalties across any safety categories for this ingredient.
Your Skin
Skin Compatibility
Our Assessment
Verdict
This ingredient is valuable for its targeted anti-acne efficacy, attributed to its dual action against *Cutibacterium acnes* and inflammatory pathways.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources